亨迪药业直线拉升20%涨停，多瑞医药涨超13%，广济药业、特一药业、哈三联、辰欣药业涨停。 (本文来自第一财经) ...

Core Viewpoint - The A-share market continues to see an upward trend in flu-related stocks, driven by rising flu activity and concerns over a potentially severe flu season this year [1] Group 1: Stock Performance - Hendi Pharmaceutical has seen a rise of over 18% - Dori Pharmaceutical has increased by over 11% - Guangji Pharmaceutical and Te Yi Pharmaceutical have hit the 10% daily limit up - Chenxin Pharmaceutical has also increased by over 6% - Notably, Guangji Pharmaceutical has achieved two consecutive limit-up days [1] Group 2: Flu Activity and Expert Insights - The China CDC reported that flu activity in northern provinces is currently low, while southern provinces are experiencing an increase - Overall, respiratory disease incidence is showing a slow upward trend nationwide - Experts indicate that the main flu strain this year is likely to be the H3N2 subtype, which was largely absent last year, leading to lower immunity levels in the population - Many experts believe that this year's flu season may arrive earlier and result in a higher number of infections [1]

证券代码：301075 证券简称：多瑞医药 公告编号：2025-088 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的进展公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用最高不超过人民币 32,000 万元（含本数）的闲 置募集资金进行现金管理，用于购买安全性高、流动性好、不影响公 司正常经营的理财产品。使用期限为自公司董事会审议通过之日起 12 个月内，在上述使用期限及额度范围内，资金可循环滚动使用。 在额度范围内授权公司法定代表人及其授权人士签署相关合同文件， 授权期限自董事会审议通过之日起 12 个月内有效。该事项已经公司 董事会、监事会审议通过，保荐机构中信证券股份有限公司对公司使 用部分暂时闲置募集资金进行现金出具了明确的核查意见。具体内容 详见于巨潮资讯网（www.cni ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-082 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的进展公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用最高不超过人民币 32,000 万元（含本数）的闲 置募集资金进行现金管理，用于购买安全性高、流动性好、不影响公 司正常经营的理财产品。使用期限为自公司董事会审议通过之日起 12 个月内，在上述使用期限及额度范围内，资金可循环滚动使用。 在额度范围内授权公司法定代表人及其授权人士签署相关合同文件， 授权期限自董事会审议通过之日起 12 个月内有效。该事项已经公司 董事会、监事会审议通过，保荐机构中信证券股份有限公司对公司使 用部分暂时闲置募集资金进行现金出具了明确的核查意见。具体内容 详见于巨潮资讯网（www.cni ...

证券之星消息，10月16日化学制药板块较上一交易日上涨0.45%，向日葵领涨。当日上证指数报收于 3916.23，上涨0.1%。深证成指报收于13086.41，下跌0.25%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 9.00 | 10.97% | 418.56万 | | 36.12亿 | | 301075 | 多瑞医药 | 50.80 | 10.63% | 7.46万 | | 3.72亿 | | 002370 | 亚太药业 | 7.55 | 10.06% | 18.57万 | | 1.40亿 | | 002793 | 罗欣药业 | 5.53 | 9.94% | 41.35万 | | 2.22亿 | | 688758 | 赛分科技 | 18.62 | 9.02% | 13.30万 | | 2.55亿 | | 300006 | 莱美药业 | 4.80 | 7.14% | 80.47万 | | 3.81亿 | | 00 ...

在河北的自行车产业里，他是白手起家的知名企业家；在医药资本市场，他是一个陌生来客。 王庆太，这位从收废铁起步，一直在自行车领域积攒身家的企业家，将成为医药上市公司多瑞医药（301075.SZ）的新实控人。 与他同行的两位一致行动人，背景也集中在建筑行业，均无医药背景。而这个"门外汉"团队将接手的多瑞医药正陷入经营困境，公司核心产品收入几近腰 斩，上市后业绩连年下滑，去年迎来了上市以来的首次年度亏损。 10月14日和15日，多瑞医药的股价受实控人将变更的消息影响呈现大幅变化。 公司将迎"造车"的新实控人 近日，多瑞医药正式公告了新实际控制人的身份。 公告显示，公司控股股东西藏嘉康及其一致行动人舟山清畅与自然人王庆太、崔子浩、曹晓兵签署了《股份转让协议》，约定由西藏嘉康及舟山清畅向受 让方合计转让上市公司29.60%的股份。本次股份协议转让的价格为32.064元/股，股份转让总价款（含税）共计人民币7.59亿元。 同时，西藏嘉康将以所持有的上市公司1944万股的无限售条件流通股份（占上市公司股份总数的24.30%）申报预受要约。自协议转让股份过户完成之日 至要约收购完成之日，西藏嘉康放弃前述股份的表决权。 本次要 ...

在河北的自行车产业里，他是白手起家的知名企业家；在医药资本市场，他是一个陌生来客。 王庆太，这位从收废铁起步，一直在自行车领域积攒身家的企业家，将成为医药上市公司多瑞医药（301075.SZ）的新实控人。 与他同行的两位一致行动人，背景也集中在建筑行业，均无医药背景。而这个"门外汉"团队将接手的多瑞医药正陷入经营困境，公司核心产品收入几近腰 斩，上市后业绩连年下滑，去年迎来了上市以来的首次年度亏损。 10月14日和15日，多瑞医药的股价受实控人将变更的消息影响呈现大幅变化。 具体来看，10月14日，公司股票复牌后，股价大幅高开，开盘即上涨超12%，当日报收42.06元/股，保持4.94%的涨幅。10月15日，多瑞医药报收45.92元/ 股，上涨了9.18%。10月16日，多瑞医药盘中快速上涨，5分钟内涨幅超过2%，一度上涨19.71%，截至午间收盘，股价涨9.82%，报50.43元。 王庆太 图片来源：视频截图 公司将迎"造车"的新实控人 近日，多瑞医药正式公告了新实际控制人的身份。 公告显示，公司控股股东西藏嘉康及其一致行动人舟山清畅与自然人王庆太、崔子浩、曹晓兵签署了《股份转让协议》，约定由西藏嘉康及舟山 ...

每经记者｜陈星 每经编辑｜魏官红 在河北的自行车产业里，他是白手起家的知名企业家；在医药资本市场，他是一个陌生来客。 王庆太，这位从收废铁起步，一直在自行车领域积攒身家的企业家，将成为医药上市公司多瑞医药 （301075.SZ，股价45.92元，市值36.74亿元）的新实控人。 与他同行的两位一致行动人，背景也集中在建筑行业，均无医药背景。而这个"门外汉"团队将接手的多 瑞医药正陷入经营困境，公司核心产品收入几近腰斩，上市后业绩连年下滑，去年迎来了上市以来的首 次年度亏损。 10月14日和15日，多瑞医药的股价受实控人将变更的消息影响呈现大幅变化。 具体来看，10月14日，公司股票复牌后，股价大幅高开，开盘即上涨超12%，当日报收42.06元/股，保 持4.94%的涨幅。10月15日，多瑞医药报收45.92元/股，上涨了9.18%。公司将迎"造车"的新实控人 近日，多瑞医药正式公告了新实际控制人的身份。 公告显示，公司控股股东西藏嘉康及其一致行动人舟山清畅与自然人王庆太、崔子浩、曹晓兵签署了 《股份转让协议》，约定由西藏嘉康及舟山清畅向受让方合计转让上市公司29.60%的股份。本次股份 协议转让的价格为32. ...

Core Viewpoint - The control change at Duori Pharmaceutical involves new shareholders without pharmaceutical experience, raising uncertainties about the company's future performance [1][2]. Group 1: Control Change Details - Duori Pharmaceutical announced a control change plan on October 14, with the new controlling shareholders being Wang Qingtai, Cui Zihao, and Cao Xiaobing, who are natural persons [1]. - The previous controlling shareholders, Xizang Jiakang and Zhoushan Qingchang, are transferring shares at a price of 32.064 yuan per share, and Wang Qingtai and Cao Xiaobing plan to make partial tender offers to other shareholders [1]. - The original controlling shareholders have made performance commitments, indicating expectations for the new shareholders to improve the company's performance amid current operational pressures [1]. Group 2: Financial Performance and Challenges - Duori Pharmaceutical's financial performance has been declining, with a projected 28.02% decrease in revenue for 2024 and a net loss of 0.63 billion yuan [2]. - The first half of 2025 also showed significant declines in both total revenue and net profit [2]. - The introduction of new investors is seen as an attempt to seek transformation, but the lack of pharmaceutical industry experience among the new controlling shareholders may hinder their ability to lead the company effectively [2]. Group 3: Strategic Considerations - The new controlling shareholders come from diverse fields such as bicycle manufacturing, construction, and technology, which may not translate well into the pharmaceutical sector [2]. - Duori Pharmaceutical aims to leverage the operational management experience and resource advantages of the new investors to aid in its development [2]. - The agreement among the new shareholders to prioritize Wang Qingtai's opinions in decision-making may enhance efficiency but could also lead to overly centralized decision-making risks [2].

Core Viewpoint - The control change at Duorui Pharmaceutical aims to introduce investors who recognize the company's value and development prospects, with the hope of leveraging their operational management experience and resource advantages to assist in the company's growth [3] Group 1: Control Change Details - Duorui Pharmaceutical announced a control change plan on October 14, with the current controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., transferring shares to three individuals: Wang Qingtai, Cui Zihao, and Cao Xiaobing [1] - The share transfer involves a total of 23.68 million shares, accounting for 29.60% of the company's total equity, at a price of 32.064 yuan per share [1] - Following the transfer, the new controlling shareholders will hold 29.60% of the shares and corresponding voting rights, while Tibet Jiakang and its partner will retain 11.98% of the voting rights [1] Group 2: New Shareholders' Background - The new actual controllers have diverse backgrounds: Wang Qingtai is involved in bicycle manufacturing and technology investments, Cao Xiaobing has experience in construction and technology, and Cui Zihao has a background in construction and real estate [2] - The three new controllers signed a concerted action agreement, agreeing to follow Wang Qingtai's opinions when exercising voting rights [2] Group 3: Performance Commitments - Tibet Jiakang made significant performance commitments for Duorui Pharmaceutical, including a minimum revenue of 150 million yuan for 2025 and a maximum net loss of 90 million yuan [2] - For 2026, the commitments include a minimum revenue of 150 million yuan and a net profit of at least 15 million yuan, while for 2027, the targets are set at 200 million yuan in revenue and a net profit of at least 21 million yuan [2] - If the company fails to meet the cumulative net profit targets, Tibet Jiakang is obligated to provide cash compensation based on the shortfall [2] Group 4: Financial Performance - Duorui Pharmaceutical has faced significant financial pressure, reporting a revenue of 241 million yuan in 2024, a year-on-year decline of 28.02%, and a net loss of 63 million yuan [2] - In the first half of 2025, the company achieved total revenue of 107 million yuan, down 29.13% year-on-year, with a net loss of 43 million yuan [2]